Case Number:

IPR2021-00326

Case Type:

IPR

Status:

Institution Denied

Petitioner:

Lupin, Ltd.

Patent Owner:

Amgen Inc.

Tech Center:

1600

1. Filed: December 15, 2020 00:00

   Coverage

   1. July 13, 2021

      PTAB Won't Review Amgen Patent On Chemotherapy Drugs

      Amgen has escaped an attempt to torpedo a patent that covers its chemotherapy-easing drugs Neupogen and Neulasta after the Patent Trial and Appeal Board found Lupin's challenge failed to prove any of the patent's claims were not patentable.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login